GlassScriptPhysician profile
Carli Vincent
NPI 1760069918
$1,040.53
in general payments reported to CMS, 2019-2025
19 companies · $923 in 2025
The $923 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $118 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $230.26 | 2025 | |
| Pfizer INC. | $182.86 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $77.27 | 2024-2025 | Belbuca, Jornay Pm |
| Merck Sharp & Dohme LLC | $76.27 | 2025 | Capvaxive, Gardasil 9, Enflonsia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.79 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.61 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $50.18 | 2025 | Airsupra |
| Novo Nordisk INC | $44.30 | 2025 | Wegovy |
| Lilly USA, LLC | $35.35 | 2025 | Mounjaro, Zepbound |
| Abiomed | $33.03 | 2025 | |
| Exact Sciences Corporation | $29.78 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $28.25 | 2025 | Voquezna |
| Acadia Pharmaceuticals INC | $23.82 | 2025 | Nuplazid |
| Seqirus USA INC | $23.28 | 2025 | Fluad, Flucelvax |
| Janssen Pharmaceuticals, INC | $21.41 | 2024 | Spravato |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.29 | 2025 | |
| Glaxosmithkline, LLC. | $19.37 | 2025 | Penmenvy, Bexsero |
| Viiv Healthcare Company | $19.06 | 2024 | Apretude |
| Edwards Lifesciences Corporation | $15.35 | 2025 | Sapien 3 Ultra Resilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carli Vincent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.